Watch Mary Hesdorffer, the Meso Foundation’s executive director and mesothelioma expert, in this opening presentation at the 2015 International Symposium on Malignant Mesothelioma. In this video, she discusses the state of mesothelioma research and treatment options. Her discussion begins with a focus on clinical trials. With 92 open clinical trials for mesothelioma, of which 55 […]
The Meso Foundation is optimistic about the results of the Phase 1b trial of pembrolizumab for PD-L1-positive advanced solid tumors, which were announced at the most recent meeting of the American Association for Cancer Research (AACR).
Dr. Evan W. Alley, MD, PhD, co-director of the Penn Mesothelioma and Pleural Program, reported the results of a Phase […]
We are excited to announce that the 2015 recipient of the Meso Foundation’s June Breit and Jocelyn Farrar Outstanding Nurse Award is Joanne Redondo of the Hillman Cancer Center.
In January, we introduced our second annual campaign to choose a recipient of the June Breit and Jocelyn Farrar Outstanding Nurse Award. We began seeking a recipient […]
This year, the Meso Foundation has partnered with the National Cancer Institute (NCI) to co-host the International Symposium on Malignant Mesothelioma. As a result, the conference will be hosted on the grounds of the National Institutes of Health (NIH) in Bethesda, Maryland. The NIH is one of the world’s foremost medical research centers.
This conference is […]
by Lee Krug, MD, Memorial Sloan Kettering Cancer Center
This month, a notification was sent to investigators on the DETERMINE Trial that accrual will be completed by the end of October. DETERMINE is an international, randomized trial comparing treatment with an immunotherapy drug called tremelimumab to treatment with placebo as second or third line therapy in […]